GALT
NASDAQ · Biotechnology
Galectin Therapeutics Inc
$3.44
-0.09 (-2.55%)
Open$3.50
Previous Close$3.53
Day High$3.55
Day Low$3.20
52W High$7.13
52W Low$2.03
Volume—
Avg Volume420.9K
Market Cap356.00M
P/E Ratio—
EPS$-0.41
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+276.7% upside
Current
$3.44
$3.44
Target
$12.96
$12.96
$9.51
$12.96 avg
$17.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 42.71M | 37.98M | 43.70M |
| Net Income | -4,071,906 | -4,331,190 | -4,441,576 |
| Profit Margin | -9.5% | -11.4% | -10.2% |
| EBITDA | -6,278,520 | -5,337,134 | -5,924,921 |
| Free Cash Flow | -4,174,488 | -3,744,064 | -5,531,991 |
| Rev Growth | +12.9% | +2.3% | +21.5% |
| Debt/Equity | 0.88 | 1.10 | 1.06 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |